1 Recommendations
1.1 Cobimetinib in combination with vemurafenib is not recommended within its marketing authorisation for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.
1.2 This guidance is not intended to affect the position of patients whose treatment with cobimetinib in combination with vemurafenib was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.